Eric Schmidt

Michael Schmidt

Sudan Loganathan

Dingding Shi

Greg Harrison

Gregory Renza

Jenna Li

Kelly Shi

Leonid Timashev

- ADC Therapeutics is a commercial-stage antibody-drug conjugate company focused on its lead asset, **ZYNLONTA**, which is approved for diffuse large B-cell lymphoma (DLBCL) and is projected to achieve **$600 million to $1 billion** in peak sales.  **[1771910_tx_380782_0]** 
- The company anticipates key clinical readouts and regulatory milestones for ZYNLONTA within the next 6-12 months, including data from the Phase 3 **LOTIS-5 study** in second-line DLBCL and the Phase 2 **LOTIS-7 study** (ZYNLONTA + glofitamab).  **[1771910_tx_380782_0]**  Initial LOTIS-7 data showed an **87% complete response rate**.  **[1771910_tx_380782_3]** 
- ADC Therapeutics also provided updates on ZYNLONTA's progress in indolent lymphomas, with initial data showing a **97% overall response rate** and **77% complete response rate** in follicular lymphoma, and a **70% complete response rate** in marginal zone lymphoma.  **[1771910_tx_380782_5]** 
- The company reported a cash position of **$265 million** at the end of Q2, providing a cash runway into **2028**, with multiple potential revenue catalysts expected by the first half of **2027**.  **[1771910_tx_380782_6]**

ADC Therapeutics Discusses ZYNLONTA Clinical Programs and Financial Outlook

ADC Therapeutics (ADCT)